Results from molecular analysis for therapy choice (MATCH) arm I: Taselisib for PIK3CA-mutated tumors.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.101
Abstract: 101Background: MATCH is a trial that assigns patients (pts) with solid tumors, lymphomas, or multiple myeloma to specific targeted therapies based on genetic alterations identified in fresh tumor b... read more here.
Keywords: analysis therapy; match; molecular analysis; therapy choice ... See more keywords